Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Axsome Thera (AXSM)

Axsome Thera (AXSM)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,557,391
  • Shares Outstanding, K 34,509
  • Annual Sales, $ 0 K
  • Annual Income, $ -30,970 K
  • 60-Month Beta 2.84
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 229.17

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.45
  • Number of Estimates 4
  • High Estimate -0.37
  • Low Estimate -0.50
  • Prior Year -0.32
  • Growth Rate Est. (year over year) -40.63%

Price Performance

See More
Period Period Low Period High Performance
1-Month
24.15 +101.86%
on 11/13/19
49.30 -1.12%
on 12/10/19
+23.29 (+91.48%)
since 11/08/19
3-Month
13.64 +257.40%
on 10/01/19
49.30 -1.12%
on 12/10/19
+24.12 (+97.93%)
since 09/10/19
52-Week
1.94 +2,412.89%
on 12/27/18
49.30 -1.12%
on 12/10/19
+45.36 (+1,338.05%)
since 12/10/18

Most Recent Stories

More News
Biotech Stock Roundup: Pipeline Updates From BIIB, AXSM, CARA, Collaborations & More

Key highlights of the past week include regulatory and pipeline updates along with collaboration deals.

MRK : 89.10 (+0.43%)
SGEN : 113.98 (-0.13%)
CARA : 16.87 (+3.75%)
BIIB : 297.20 (+0.56%)
AXSM : 48.75 (+8.02%)
INCY : 95.72 (+0.98%)
Biotechs Move Forward Developing Latest Targeted Therapies for Acute Myeloid Leukemia

So it is not surprising that there is a lot of money and research resources being devoted to find new therapies for Acute Myeloid Leukemia (AML), many of which are in the targeted drugs arena. AML is the...

MBRX : 1.02 (-1.92%)
BOLD : 59.51 (+0.32%)
OTLK : 1.14 (-1.72%)
AXSM : 48.75 (+8.02%)
QURE : 64.99 (+3.16%)
Axsome Narcolepsy Candidate Meets Phase II Goal, Stock Up

Axsome (AXSM) announces data from a phase II study evaluating AXS-12 in narcolepsy patients, demonstrating statistically significant reduction in weekly cataplexy attacks.

NVS : 92.80 (+0.29%)
AXSM : 48.75 (+8.02%)
JAZZ : 150.06 (-0.85%)
TEVA : 9.49 (-3.36%)
Implied Volatility Surging for Axsome (AXSM) Stock Options

Investors need to pay close attention to Axsome (AXSM) stock based on the movements in the options market lately.

AXSM : 48.75 (+8.02%)
Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in CONCERT Phase 2 Trial in Narcolepsy

Demonstrated statistically significant reduction in cataplexy attacks compared to placebo (p

AXSM : 48.75 (+8.02%)
Axsome Therapeutics to Host Investor R&D Call with Key Opinion Leaders Focusing on AXS-07 and the Unmet Needs in the Acute Treatment of Migraine

Company to host conference call on Monday, November 25 at 9:00 AM Eastern

AXSM : 48.75 (+8.02%)
Axsome: 3Q Earnings Snapshot

NEW YORK (AP) _ Axsome Therapeutics Inc. (AXSM) on Thursday reported a loss of $19.1 million in its third quarter.

AXSM : 48.75 (+8.02%)
Axsome Therapeutics Reports Third Quarter 2019 Financial Results and Provides Business Update

GEMINI Phase 3 placebo-controlled trial of AXS-05 in MDD completed enrollment and on track for readout of topline results by year-end 2019

AXSM : 48.75 (+8.02%)
Axsome Therapeutics to Report Third Quarter 2019 Financial Results on November 7, 2019

Axsome to host conference call and webcast on Thursday, November 7, 2019 at 8:00 AM Eastern Time

AXSM : 48.75 (+8.02%)
Axsome Therapeutics Announces Results of MINDSET Physician Survey Affirming Unmet Need and Favorable Profile of AXS-07 in the Acute Treatment of Migraine

Majority of physicians indicate improved efficacy is most significant unmet need in the acute treatment of migraine

AXSM : 48.75 (+8.02%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy and ranks in the Top 1% of all short term signal directions.

Long term indicators fully support a continuation of the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Trade AXSM with:

Business Summary

Axsome Therapeutics, Inc. is a biopharmaceutical company. The company is focused on developing novel therapies for the management of pain and other central nervous system disorders. Its product candidate portfolio consists of AXS-02 and AXS-05 which are in clinical trial stage. Axsome Therapeutics, Inc....

See More

Key Turning Points

2nd Resistance Point 51.68
1st Resistance Point 50.21
Last Price 48.75
1st Support Level 46.37
2nd Support Level 44.00

See More

52-Week High 49.30
Last Price 48.75
Fibonacci 61.8% 31.21
Fibonacci 50% 25.62
Fibonacci 38.2% 20.03
52-Week Low 1.94

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar